The $350 million gross raise provides substantial cash runway for a clinical-stage biotech, but the 8.8% discount to market price and the proximity to the prior day's 424B5 filing signals that the company needed to move quickly to raise capital. Monitor upcoming clinical data readouts and pipeline milestones for signs of execution risk on the use of proceeds.
Price Chart
Executive Summary
Spyre Therapeutics entered into an underwriting agreement to sell 4,117,648 shares of common stock at $85.00 per share, with gross proceeds of approximately $350.0 million. The offering, which closed on October 7, 2026, follows a 424B5 filing from the prior day and provides capital to fund pipeline advancement including SPY072 for hidradenitis suppurativa, preclinical studies, clinical trials, and Phase 3 readiness. The dilutive equity raise is a notable event for a pre-revenue biotech, extending cash runway but increasing share count by approximately 4.1 million shares.
Key Financial Metrics
Key Facts
- Spyre Therapeutics entered into an underwriting agreement on October 5, 2026 to sell 4,117,648 shares of common stock at $85.00 per share
- Gross proceeds expected to be approximately $350.0 million before underwriting discounts and commissions
- Underwriters have a 30-day option to purchase up to an additional 617,647 shares
- Net proceeds to company after underwriting discounts ($21.0 million) is approximately $329.0 million before expenses
- Offering priced at $85.00 per share, a 8.8% discount to the last reported sale price of $93.19 on October 2, 2026
- Proceeds intended to fund pipeline programs in Gastroenterology, Rheumatology, and Dermatology, including SPY072 for hidradenitis suppurativa, plus preclinical studies, clinical trials, manufacturing, and Phase 3 readiness
- Offering closed on October 7, 2026
- This 8-K follows a 424B5 prospectus supplement filed October 6, 2026 for the same offering
Financial Impact
Approximately $329 million net proceeds to company after underwriting discounts, before expenses. Dilution of ~4.1 million shares (plus up to 0.6 million additional shares if option exercised).
Risk Factors
- Dilution of approximately 4.1 million shares reduces per-share value for existing shareholders
- Pre-revenue biotech with no approved products; no revenue or earnings data in this filing to offset dilution
- Potential for full exercise of underwriter option could add additional dilution if option is exercised in full
- No financial statements or revenue figures provided in this filing to assess current financial health
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-065291 |
| Exhibit: exhibit51-8xk.htm | 0001628280-26-065291 |
| Document: syre-20261005.htm | 0001628280-26-065291 |
| Document: 0001628280-26-065291-index-headers.html | 0001628280-26-065291 |
| Document: 0001628280-26-065291-index.html | 0001628280-26-065291 |
| Document: 0001628280-26-065291.txt | 0001628280-26-065291 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $85.90 | awaiting T+20 | — | $92.91 (+8.16%) |
Oct 9, 2026 17d ago | SC 13D/A | $85.90 | awaiting T+20 | — | $92.91 (+8.16%) |
Oct 7, 2026 19d ago | 8-K | $80.85 | awaiting T+20 | — | $92.91 (−14.92%) |
Oct 6, 2026 20d ago | 424B5 | $80.85 | awaiting T+20 | — | $92.91 (−14.92%) |
Oct 5, 2026 20d ago | Press Release | $80.11 | awaiting T+20 | — | $92.91 (−15.98%) |
Oct 5, 2026 21d ago | 424B5 | $80.11 | awaiting T+20 | — | $92.91 (−15.98%) |
Oct 5, 2026 21d ago | Press Release | $80.11 | awaiting T+20 | — | $92.91 (−15.98%) |
Oct 2, 2026 23d ago | Insider Cluster | $92.72 | awaiting T+20 | — | $92.91 (−0.20%) |
Sep 3, 2026 7w ago | Insider Cluster | $88.98 $92.72 | ▼ −4.20% | ▼ −3.60% | $92.91 (−4.42%) |
Aug 10, 2026 10w ago | Insider Cluster | $102.74 $86.93 | ▲ +15.39% | ▲ +14.33% | $92.91 (+9.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers